



Published in final edited form as:

Med Decis Making. 2018 November ; 38(8): 1027–1039. doi:10.1177/0272989X18806493.

Effects of emotion on medical decisions involving tradeoffs

Erin M. Ellis, PhD, MPH^a, William M. P. Klein, PhD^b, Edward Orehek, PhD^c, and Rebecca A. Ferrer, PhD^a

^aBasic Biobehavioral and Psychological Sciences Branch, Behavioral Research Program, National Cancer Institute

^bOffice of the Associate Director, Behavioral Research Program, National Cancer Institute

^cDepartment of Psychology, University of Pittsburgh

Abstract

Risk perceptions for a disease can motivate use of medications that reduce disease risk. However, these medications are often accompanied by elevated risks for other adverse health effects, and perceived risk of these side effects may also influence decisions. Emotions experienced at the time of a decision influence risk judgments and decision making, and may be important to examine in these tradeoff contexts. This study examined the effect of experimentally-induced fear and anger on risk perceptions and willingness to use a hypothetical medical treatment that attenuates risk of one condition, but increases the risk for another.

Participants ($N=1948$) completed an induction of fear, anger, or neutral emotion, and then read about a hypothetical medication that reduced risk for one health condition, but increased risk for another, and indicated their willingness to use it. Deliberative, experiential, and affective risk perceptions about both health conditions were measured, conditional on taking and not taking the medication.

Fear condition participants were more willing to take the medication than those in the neutral condition, $\beta=0.14$, $p=.009$, 95% CI (0.036, 0.25). Fear also increased deliberative, experiential, and affective risk when conditioned on *not using* the medication, $p<.05$. In contrast, anger did not influence willingness to use the medication, $p=.22$, and increased deliberative and affective risk of side effects when conditioned on *using* the medication, $p<.05$.

As one of the first studies to examine how emotion influences tradeoff decision making, these findings extend our understanding of how fear and anger influence such decisions.

Introduction

Many medical treatments lower the risk of one health condition yet increase the risk of another. Tamoxifen therapy reduces breast cancer risk, but raises endometrial cancer risk.¹ Hormone replacement therapy reduces colorectal cancer risk, but raises breast cancer risk.²

Corresponding author: Erin M. Ellis, 9609 Medical Center Drive, Rockville, MD 20850, Phone: (240) 276-5646, Fax: (240) 276-7883.

Department(s) and institution(s) where the work was done: University of Pittsburgh and National Cancer Institute

Meeting(s) at which the work was presented: Society of Behavioral Medicine 2017 Annual Meeting

Patients with slow growing or early stage cancers, such as prostate, must decide between treatment options that pose different combinations of tradeoffs, such as the increased anxiety that arises with active surveillance, or the side effect risks of surgery or radiation. These tradeoff decisions are ubiquitous, and risk-related judgment and decision-making in this context is different from those involving no or minimal risk of adverse effects, such as decisions to avoid sedentary behavior. For instance, people have an aversion to medication side effects that is particularly insensitive to objective estimates of likelihood and severity, and express less willingness to use medications that have side effects, regardless of net effects on risk.³⁻⁸ Also, these decisions often occur in contexts of clinical equipoise where there is no objectively superior option, or where a clinically superior option may exist, but patients may interpret their risks differently based on unique circumstances. Thus, there may not be a recommended course of action for all individuals, making a more nuanced understanding of decision making critical.

Because these medically-relevant tradeoff decisions are often prompted by a new diagnosis, decline in prognosis, or other change in health status, they may be influenced by heightened emotions, such as fear or anger, that these events evoke.^{9,10} Evidence suggests that such medical decisions can be particularly affect-laden.¹¹⁻¹⁴ Despite this real-world relevance, as well as the influence of anger and fear on risk propensity and decision making in non-tradeoff scenarios,^{15,16} little work has examined how emotions influence risk-related judgements and decision making in tradeoffs. Greater understanding of how emotions influence these choices may inform support tools and risk communication techniques for those facing high-stakes medical tradeoffs. This research may also advance fundamental knowledge of how emotions influence decision making when all options convey risk.

Discrete emotions

Anger and fear experienced at the time of a decision influence risk judgments, decision making, and behavior. Although both fear and anger are negative emotions, they have opposite certainty and control appraisal tendencies, which are the dimensions of emotions known to influence risk judgements and decision making.¹⁷⁻²⁰ Anger conveys a sense of high certainty and control and tends to produce optimistic risk perceptions and greater risk propensity. Because it is characterized by the goal to deter or right a transgression, it also often results in an orientation toward approaching action.^{18,21} In contrast, fear is associated with a sense of uncertainty and low controllability, and thus, increases risk perceptions and risk-averse behavior. Because it is characterized by the goal of protecting oneself against an existential threat, it often (but not always; see^{15,22,23} for reviews in health contexts) results in an orientation toward avoiding action.^{18,19,24} Importantly, anger and fear are thought to influence decision-making similarly regardless of whether the emotion is integral (evoked by a decision) or incidental (evoked by another source).^{18,19}

Risk perceptions

Perceptions of susceptibility to threat (i.e., risk perceptions), are a robust predictor of decisions and behavior across health contexts. However, risk perception is not a unidimensional construct, and emotions may influence some types of risk perceptions differently than others. For instance, risk perceptions can be deliberative (perceptions of the

likelihood of a threat, often numerically-based, and reflecting elaborated information processing), affective (worry or other emotions evoked by considering the risk), or experiential (intuitive or gist-based judgments about risk) in nature.^{25,26} Although each represents a reaction to threat, they are conceptually and empirically distinct, and uniquely predict behavior, sometimes even in opposite directions.^{26–30} Given this, as well as evidence that affectively-based interventions can influence affective and cognitive factors differently, anger and fear may have different effects on deliberative, affective, and experiential risk perceptions, as well as their associations with behavior.

Emotions may also influence risk perceptions differently depending on the behavioral conditions that inform the risk perception. For example, a smoker may hold two types of risk perceptions: her risk if she continues to smoke (i.e., does not take action), and her risk if she quits (i.e., takes action). If unconditional risk perceptions are assessed without specifying any behavioral conditions, such as quitting or continuing to smoke, she is likely to report the version of risk perception conditional on whichever future behavioral pattern she deems most likely. Thus, it is not possible to infer from her response whether her risk perception is conditional on an action (quitting) or avoidance/inaction (continuing to smoke) orientation.^{31–33} For tradeoff decisions, each choice confers risk, so anger and fear may not influence decision making solely according to their risk-taking (anger) and risk-avoiding (fear) appraisal tendencies. Instead, the effects of anger and fear on tradeoff decision making may also reflect these emotions' different action orientations. Because anger motivates an action orientation, it may have a greater effect on risk perceptions that are conditioned on *taking action*, whereas fear, with its action-avoidant orientation, may have a greater effect on risk perceptions conditioned on *not taking action*. By assessing conditional risk perceptions, the effects of both the risk and action orientations of anger and fear can be examined.

Objectives and research questions

This study examined the effect of experimentally-induced fear and anger on willingness to use a hypothetical preventive medical treatment said to attenuate risk of one condition yet increase risk for another. Given their risk appraisal tendencies, we hypothesized that anger would decrease willingness to use the medication, whereas fear would increase willingness.

We also conducted exploratory analyses to examine the effects of fear and anger on conditional affective, deliberative, and experiential risk perceptions, and to test whether they mediated emotions' effects on willingness. We hypothesized that side effect risk would more strongly influence willingness than perceived risk of the target condition. We also expected that fear and anger would influence inaction and action-oriented risk perceptions, respectively. We did not have hypotheses regarding which type(s) of risk perception (i.e., perceived risk of side effects or target condition; deliberative, experiential, or affective risk) would be influenced by the induction.

Method

Procedure

To increase the likelihood that scenarios would be personally relevant, participants ($N=1,948$) were assigned to one of two health contexts based on their age. Those aged 40 years and over ($n=575$) read about a hypothetical medical treatment related to chronic diseases, and those under 40 years ($n=1,373$) read about a treatment related to sexual health. Once assigned to a health context, a 3 (emotion condition) \times 2 (health condition) between-groups experimental design was used to randomly assign participants to one of six conditions that differed in emotion (anger ($n=633$), fear ($n=638$), or neutral ($n=677$) emotion) and the health condition that was targeted by the medication (i.e., for which risk was lowered). Those aged 40 or over were assigned to cancer ($n=294$) or heart disease ($n=281$); those under 40 were assigned to sexually transmitted infections (STIs; $n=681$) or sexual pleasure loss ($n=692$). The health condition not targeted by the medication served as the side effect.

The study was conducted online in two separate waves administered approximately six months apart. Participants were recruited using Amazon's Mechanical Turk (MTurk), an online platform that has been used successfully to recruit research samples with acceptable measurement reliability and validity. MTurk workers with a US-based IP address were eligible for the study. Participants were remunerated \$1.00 USD. A post hoc sensitivity power analysis estimated that our sample size ($N=1,948$) was large enough to detect a very small effect of emotion condition on willingness (Cohen's $F = 0.087$), given the specified alpha (.05) and desired power (.95).

A cover story in which the protocol was described as two separate studies was constructed to reduce demand characteristics.³⁴ Participants first completed individual difference measures and an autobiographical emotion induction task shown to be an efficient means of inducing fear and anger. Participants wrote for 3–5 minutes about a time in the past year they felt the angriest [most fearful], or about a room in their house (neutral condition).³⁵ As the ostensibly second study, participants read the hypothetical medication scenarios and completed questionnaires designed to assess their interpretation of the risk information, willingness to use the medication, and conditional risk perceptions.

Medication scenario

All participants completed both a benchmark and tradeoff scenario about a hypothetical daily medication in counterbalanced order. A pilot study was conducted to determine the specific probabilities of risk and benefit that produced a meaningfully complex decision, as evidenced by large variability in willingness to use the medication. Using these findings, the medication in the benchmark scenario reduced participants' risk of getting the target condition from 20 to 6 out of 100 people, and had no side effects. This served as a measure of participants' willingness to use a medication in the absence of negative consequences.

The medication in the tradeoff scenario reduced participants' risk of getting the target condition the same amount, but also increased their risk of experiencing a side effect from 6 to 15 out of 100 people. In the chronic disease scenarios, the medication reduced the risk of

cancer and increased the risk of heart disease, or the opposite. In the sexual health scenarios, the medication reduced the risk of getting an STI and increased the risk of experiencing a loss in sexual pleasure, or the opposite. Counterbalancing across participants which disease was the target condition and which was the side effect enabled us to test whether disease-specific beliefs, such as fear about cancer, influenced decision making, and ensured choices did not reflect a default effect (i.e., avoiding the loss of what one already has or would have had). Both scenarios were accompanied by arrays that visually depicted the change in risk for each health condition (Figure 1).

Measures¹

Risk perceptions.—Each of three deliberative, three experiential, and one affective risk perception item was assessed four times: conditional on taking and not taking the medication, and about the hypothetical medication’s targeted and side effect conditions. All items used a 7-point Likert-type scale. Deliberative risk perception items included, “If you [did not take/took] this pill, how likely would you be to get [target condition/side effect] in the future?” with response options ranging from (1) *very unlikely* to (7) *very likely*. Experiential items included, “If you [did not take/took] this pill, how easy would it be for you to imagine yourself getting [target condition/side effect]?” with response options ranging from (1) *not at all easy* to (7) *extremely easy*. Affective risk perceptions were assessed with the item: “If I [did not take/took] this pill and then got [target condition/side effect], I would be devastated” with response options ranging from (1) *strongly disagree* to (7) *strongly agree*. For both the deliberative and experiential items, four scale means were computed, which represented risk perceptions about the target condition and side effect, conditional on taking and not taking the medication (see Discussion for possible implications of conditioning affective risk items).

Medication use decision.—Willingness to use the medication was assessed with the item, “If this were a real choice, would you take this pill?” on a scale from (1) *definitely would not* to (7) *definitely would*. This item was assessed after both the benchmark and tradeoff scenario; however, due to a survey programming error, the benchmark scenario data were only available for half of participants ($n=1,004$). This error did not affect data from the tradeoff scenario.

Accuracy of risk evaluation.—The accuracy with which participants were able to recall the effect of medication on disease risk was assessed with one item, “Doctors sometimes assume that patients understand what they say without checking. According to the doctor’s numbers, how would taking this new pill affect your risk?” Five nonnumeric response options were provided, including one that reflected the correct risk estimation (e.g., “It would increase my risk of losing sexual pleasure, but reduce my risk of getting a sexually transmitted infection”), as well as an “I don’t know” option.

Responses were categorized as *correct* or *incorrect*, generating a dichotomous variable. To separately compare responses that were incorrect and also either optimistically biased or not,

¹Some individual difference scales were assessed as exploratory moderators (goal conflict, response efficacy, regulatory focus), but none was central to the research question, nor did any serve as moderators. Thus, they are not discussed further in the manuscript.

a 3-level variable was created with responses categorized as: (1) *correct* (“It would increase my risk of [side effect], but reduce my risk of [target condition]”); (2) *incorrect* (“It would increase my risk of [target condition], but reduce my risk of [side effect]” or “I don’t know”), or (3) *optimistic* (“It would decrease my risk of [side effect], and have no effect on my risk of [target condition]” or “It would decrease my risk of [target condition], and have no effect on my risk of [side effect]”).

Manipulation check.—Reporting emotion may alter the subjective experience of emotion.^{36,37} Thus, half of participants ($n=999$) were randomly assigned to complete a 4-item assessment of current mood as an induction check, providing a test of whether this assessment influenced the induction’s effects on study outcomes. Means were computed for two items that assessed fear (afraid, anxious, $r=0.73$) and anger (angry, hostile, $r=.77$).

Participant characteristics.—Age, sex (male or female), education level, race/ethnicity (five dummy codes representing five non-mutually exclusive categories; see Table 1), marital status (married/cohabitating or unmarried), self-rated health status (5-point scale), and disease history were assessed.

Analysis plan

Analyses were conducted in Stata, version 14 (StataCorp, College Station, TX). Continuous items were standardized to $M=0$ and $SD=1$. We used ANOVA and chi-square tests to determine whether participant characteristics differed across study condition, and linear regression to test whether they influenced willingness to use the medication. Characteristics that did were included as covariates in subsequent models. We also used linear regression to test whether the medication’s targeted health condition (e.g., cancer) had an effect on willingness and/or moderated the effect of emotion on willingness.

We used linear regression to test whether emotion (a 3-level variable with neutral serving as the reference category) influenced risk perceptions and willingness to use the medication. Given the number of statistical comparisons in the risk perception analyses, p-values were also corrected for multiple comparisons using the Benjamini and Hochberg (1995) procedure.³⁸ Effects were examined using a conservative false discovery rate ($Q = .05$; equal to alpha), and a less conservative rate of $Q = 0.25$.³⁹

Logistic regression models tested emotions’ effects on recall accuracy. We conducted a multinomial logistic regression using a 3-level recall accuracy variable (*correct*, *incorrect*, or *optimistic*) as the outcome to separately compare correct responders to those whose incorrect responses were or were not also optimistic.

We examined whether risk perceptions mediated the effects of induced emotions on willingness in a series of path analysis models. This approach permitted simultaneous testing of direct, indirect, and total effects. Because indirect effects are calculated as the product of two regression coefficients, they are not normally distributed and statistical estimations that require such assumptions tend to be biased. Therefore, we used a Monte Carlo method to generate sample statistics and confidence intervals based on the asymptotic sampling distribution of the indirect effect.^{40,41}

Results

Participants

Participants were 38.22 years old on average ($SD = 12.56$), and half (52.5%) were female. Three quarters (76.5%) self-identified as white; 10.0% as Asian/Pacific Islander; 8.2% as Hispanic; 7.0% as black; and 4.9% as another race. Most (82.1%) completed at least some college, with half (53.5%) having a four-year degree. No participant characteristic differed across emotion conditions, $ps > .05$ (Table 1). Aside from age, which was intended to differ across the chronic disease and sexual health arms of the study, education was the only other characteristic that differed across the two arms. Adjusting for age, education level was higher in the sexual health arm, $F(1, 873) = 6.18, p = .013$.

Manipulation check

Self-reported anger was highest in the anger condition, and fear was highest in the fear condition, suggesting the emotion induction influenced emotion as intended (see Table 1). Specifically, anger was higher in the anger condition than neutral condition, $F(1, 996) = 224.64, \omega^2 = 0.18, p < .001$, and fear condition, $F(1, 996) = 73.60, \omega^2 = 0.068, p < .001$. Fear was higher in the fear condition than in the neutral, $F(1, 996) = 114.02, \omega^2 = 0.10, p < .001$, and anger conditions, $F(1, 996) = 24.45, \omega^2 = 0.023, p < .001$.

Anger was also higher in the fear condition than in the neutral condition, $F(1, 996) = 39.55, \omega^2 = 0.037, p < .001$, and fear was higher in the anger condition than in the neutral condition, $F(1, 996) = 33.05, \omega^2 = 0.031, p < .001$, suggesting moderate crossover of the induction's effects.

Completing the measure of emotion did not moderate the effect of the emotion induction on risk perceptions and willingness to use the medication, $ps > .05$.

Willingness to use the medication

Participant characteristics.—As expected, participants were more willing to use the medication in the benchmark scenario without side effects than in the tradeoff scenario ($M = 4.20, SD = 2.11$ vs. $M = 2.54, SD = 1.75$), $t(1002) = 24.94, d = 0.79, p < .001$. In the benchmark scenario, willingness was lower among younger, Asian, and healthier participants, and higher among white and black participants, $ps < .05$ (Table 2). In the tradeoff scenario, willingness was lower among women, nonwhite, Asian, Hispanic, and healthier participants, $ps < .05$. In all subsequent analyses, age, sex, race/ethnicity, health status, as well as the health condition targeted by the medication are included as covariates.

Targeted health condition.—Willingness to use the medication in the tradeoff scenario differed depending on the health condition targeted. For chronic disease scenarios, participants were more willing to use the medication when the medication reduced cancer risk and increased heart disease risk than when it reduced heart disease risk and increased cancer risk ($M_{adj} = 2.98, SE = 0.10$ vs. $M_{adj} = 2.41, SE = 0.10$). For sexual health scenarios, participants were more willing to use the medication when it reduced STI risk than when it

reduced risk of losing sexual pleasure ($M_{adj} = 2.68$, $SE = 0.067$, vs. $M_{adj} = 2.28$, $SE = 0.066$). The same pattern emerged in the benchmark scenario (Table 2).

Induced emotions.—In the tradeoff scenario, participants were more willing to use the medication in the fear condition than in neutral condition ($M_{adj} = 2.67$, $SE = 0.070$ vs. $M_{adj} = 2.42$, $SE = 0.068$), $\beta = 0.14$, $\omega^2 = 0.0030$, $p = .009$, 95% CI (0.036, 0.25). Willingness did not differ between the anger and neutral conditions, $\beta = 0.066$, $\omega^2 = 0.00019$, $p = .22$, 95% CI (−0.041, 0.17). For the benchmark scenario, there was no effect of emotion condition on willingness to use the medication, $ps > .05$. This pattern of findings was consistent across adjusted and unadjusted models (Table 2), and was not moderated by age, sex, or the medication's targeted health condition, $ps > .05$.

Recall accuracy

Overall, 72.5% of participants accurately recalled how the medication in the tradeoff scenario would influence their risk for the target condition and side effect. Participants who were older, $OR = 1.21$, $p < .001$, 95% CI (1.09, 1.34), female, $OR = 1.35$, $p = .002$, 95% CI (1.11, 1.63), white, $OR = 6.75$, $p < .001$, 95% CI (5.49, 8.30), and more educated, $OR = 1.19$, $p = .002$, 95% CI (1.06, 1.33), were more likely to accurately recall the risk information, $ps < .05$.

Participants in the fear condition were less likely to accurately recall the information compared to participants in the neutral condition, $OR = 0.68$, $p = .009$, 95% CI (0.51, 0.91), as well as the anger condition, $OR = 0.83$, $p = .034$, 95% CI (1.12, 1.41). There were no differences in accuracy between the anger and neutral conditions, $OR = 0.94$, $p = .69$, 95% CI (0.69, 1.27).

Participants who accurately recalled the risk information were less willing to take the medication, $\beta = -0.71$, $\omega^2 = 0.077$, $p < .001$, 95% CI (−0.82, −0.60). There was an indirect effect of fear on willingness via accuracy, $\beta = 0.071$, $p = .010$, 95% CI (0.017, 0.13), and a nonsignificant direct effect, $\beta = 0.17$, $p = .067$, 95% CI (−0.12, 0.36), suggesting the lower accuracy in the fear condition mediated the effect of fear on willingness.

To help elucidate why a decline in accuracy was associated with greater willingness among fearful participants, we conducted a multinomial logistic regression and separately compared *incorrect* and *optimistic* participants to a *correct* reference category. Individuals in the fear condition were no more likely than those in the neutral condition to be *incorrect*, $RR = 1.01$, $p = .92$, 95% CI (0.71, 1.46), but they were more likely to be *optimistic*, $RR = 1.56$, $p = .020$, 95% CI (1.07, 2.27), suggesting that the inaccuracies evoked by fear reflected optimistic biases. There were no differences between the anger and neutral conditions in the likelihood of providing an *incorrect* or *optimistic* versus *correct* response, $ps > .05$.

Conditional risk perceptions

Twelve conditional risk perception scales were examined, reflecting whether they were deliberative, experiential, or affective; conditional on taking or not taking the medication; and about the target condition or side effect (Table 3). Five effects of emotion condition were significant across 24 comparisons. In each case, perceived risk was higher in the fear and

anger conditions compared to the neutral condition. When conditioned on *action* (taking the medication), perceived deliberative and affective risk of the side effect was higher in the anger condition (relative to neutral), $ps < .05$. When conditioned on *inaction* (not taking the medication), deliberative and experiential risk of the side effect, as well as affective risk of the target condition were higher in the fear condition, $ps < .05$.

When effects were corrected for multiple comparisons using a conservative false discovery rate ($Q = .05$), only the effect of anger on affective risk perceptions about the side effect conditioned on action was significant. Using a less conservative false discovery rate ($Q = .25$), all five effects remained significant.

For the five risk perception scales for which the emotion condition had an effect, we used path analysis to estimate the direct effects of emotion on risk perceptions (a_a and a_f in Figure 2 and Table 4) and of risk perceptions on willingness (b in Figure 2 and Table 4), as well as the indirect effects of emotion on willingness through risk perceptions. The effect of anger on willingness was mediated by affective – but not deliberative – risk perceptions about the side effect conditioned on action, $p < .05$ (Figure 2; Table 4). The effect of fear on willingness was partially mediated by three risk perception scales conditioned on inaction, $ps < .05$. In each case, fear also had a main effect on willingness, $ps < .05$.

Discussion

This study examined the effects of experimentally-induced fear and anger on conditional risk perceptions and willingness to take risk-mitigating action in a risk tradeoff decision-making scenario: choosing whether to use a medication that reduced risk for one health condition, but increased risk for another. Overall, participants in the fear condition were more willing to take the medication than those in the neutral condition, and this effect was mediated by lower accuracy in the recall of risk information. Those in the fear condition were more likely to be inaccurate in ways that reflected optimistic biases about their risk, which is consistent with prior evidence,⁴² and may help explain why the observed decline in accuracy was associated with increased willingness.

Willingness and recall accuracy

Fear can influence information processing, reducing accuracy and attention to the most relevant risk information, and increasing attention to unrelated details instead.^{42,43} In this study, fear may have made stored knowledge (e.g., fatalistic beliefs about cancer) more accessible in the decision-making process, potentially overriding a refined assessment of the scenario's risk information.⁴⁴ This may help explain why those in the fear condition were less likely to accurately recall the risk information, and why their greater willingness was partly mediated by greater perceived risk of the side effect conditioned on inaction, a presumably irrelevant risk perception for that decision.

Another plausible complementary account, consistent with the appraisal tendency framework that informed this study, is that participants' willingness reflected an alignment of the message's loss framing with fear's risk-averse appraisal tendencies (i.e., the medication was described as risk-mitigating and fear evokes a desire to avoid risks).^{18,19,45}

Although the fear evoked by the manipulation was incidental to the threat, if it was attributed to the target health condition, these effects would be similar to the effects of integral fear/worry about health threats, as well as fear appeal interventions, as motivators of health-promoting behaviors.^{22,23,46–50} They are also consistent with related evidence that fear can serve as a form of and/or draw attention to risk information.^{15,16,44,51}

Risk perceptions

This is the first known study to examine the effects of emotion on conditional risk perceptions. Results from these exploratory analyses suggest fear and anger had small effects on some types of risk perceptions. However, given the attenuation of results after adjusting for multiple comparisons, inferences based on these results should be considered preliminary, and replication is essential. Specifically, three potentially important patterns emerged that warrant examination in future work, including the salience of side effects, the role of the emotions' action orientations, and the potentially context-specific effects of anger.

Side effects.—Four of the five effects of emotion on perceived risk involved side effects, which is consistent with research demonstrating individuals' disproportionate attention to side effect information, affectively-based aversion to them, high sensitivity to changes in side effect risk, and strong influence of side effect risk on medication decisions.^{8,52,53} Given their central focus, emotions may influence side effect risk perceptions more than other risk judgments. This may also help explain why emotion influenced willingness to use the medication in our tradeoff scenario, but not in the benchmark scenario where the medication did not have side effects.

Action orientations.—Consistent with our hypotheses, anger increased two out of three side effect risk perceptions that were conditional on taking the medication, whereas fear increased two out of three side effect risk perceptions conditional on *not* taking the medication. These findings are consistent with the emotions' action tendencies; anger increased the focus on action, and fear increased the focus on inaction, and the conditional risk perceptions changed accordingly.

These findings suggest that when both options pose risks, changes in perceived risk may depend on both the risk appraisals and action tendencies of emotions. In fact, anger's effects on risk perceptions combined with its action tendencies may help explain the nonsignificant effect of anger on willingness to use the medication. Whereas anger's action tendencies should have increased willingness, anger also increased risk perceptions conditioned on action, which may have decreased willingness. Thus, these two effects may have operated in opposing directions, essentially canceling each other out.^{54,55} These findings may have important implications for theoretical work examining the effects of emotion on decisions involving risk tradeoffs, and future work is needed to elucidate the complex roles of conflicting risk appraisals and action orientations.

Anger.—Contrary to past work in which anger facilitates optimistic risk perceptions because it is a high certainty and control emotion,^{18–20} both fear *and* anger increased risk

perceptions. If participants followed instructions and considered how the medication would affect their side effect risk independently of other factors, one possibility is that this tradeoff scenario was experienced as low-control because both using and not using the medication posed risk. Prior work has shown anger does not produce optimistic risk judgments when it is experienced as low-control,^{56,57} and the effects of anger on risk judgments are less consistent than those for fear.^{45,56,58} However, the conditional risk perception format used in the current study reduces the ability to compare current findings to past work.

Limitations

Some limitations should be considered when interpreting these findings. We did not assess attitudes about medication (e.g., perceiving daily medication as a burden) that could have also influenced willingness. There was also a six-month gap between two waves of data collection, and a coding error prohibited use of benchmark scenario data for half of participants.

Our medication scenario provided necessary methodological and experimental control, but it did not reflect the complexity of many real-world medical decisions. Although we avoided the term “side effect” in the scenarios, participants may have nonetheless interpreted their increased risk as a medication side effect, inducing side effect aversion. This side effect information (or any information unrelated to how the medication influenced target condition risk) may have reduced focus on the target condition risk information. Moreover, the current study did not consider non-health medication consequences, such as medication costs, and whether tradeoff decision making differs depending on the type of consequence. Future work would benefit from manipulating these aspects of the scenario to elucidate their unique contributions to medication decisions.

It was important that risk perception items be conditional on using or not using the medication, given our hypotheses regarding the role of action tendencies. However, this made it difficult to draw on existing work to generate *a priori* predictions, and created several dependent variables, increasing the possibility of Type 1 error. Thus, these findings should be interpreted with caution and need to be replicated. It also resulted in affective risk perception items more reflective of anticipated emotions (expectations about one’s future feelings) than the more commonly-assessed anticipatory affective reactions to a threat (current affect evoked by considering a future threat). Thus, our findings may not be conceptually comparable to prior work on affective risk perceptions.

Implications

Our tradeoff scenario aimed to mimic clinical equipoise where there is no objectively or universally superior option. Thus, neither greater nor less willingness was perceived as a “better” decision in this study. Because a universal course of action cannot be recommended for all individuals, it is important to understand how tradeoff risks are perceived, how they influence decision making, and how emotions affect these processes so that interventions can be developed. If treatment decisions made in strong emotional states are found to be inconsistent with one’s long-term goals or values, then delaying decision making until emotions have subsided, promoting effective emotion regulation, relying on others for

decision-making support, or strategically framing the risks and benefits, may be advantageous.

Although observed effects of emotion were small, they were evoked despite variability in beliefs about the health conditions, and by an induction much milder than the intense emotional states that these high-stakes medical decisions often evoke. Even these small one-time individual-level effects may translate into considerable differences in medication adherence and treatment decision making at the population level and over time. Intervening to reduce (or leverage) small unwanted (or advantageous) effects of emotions on decision making may justify the costs if they, too, are small.

This study had several strengths including its experimental design, use of conditional risk perception scales, and large diverse sample. As one of the first studies to examine the role of emotion in tradeoff decision making, the current findings extend our understanding of how fear and anger influence such decisions, and have implications for decision sciences, as well as interventions aimed at improving patient decision making and care experiences.

Acknowledgments

Financial support for this study was provided in part by internal funds from the National Cancer Institute, NIH. The funding agreement ensured the authors' independence in designing the study, interpreting the data, writing, and publishing the report.


References

1. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. *Journal of the National Cancer Institute* 1998;90:1371–88. [PubMed: 9747868]
2. Writing Group for the Women's Health Initiative I. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. *JAMA* 2002;288:321–33. [PubMed: 12117397]
3. Waters EA, Weinstein ND, Colditz GA, Emmons K. Explanations for side effect aversion in preventive medical treatment decisions. *Health Psychology* 2009;28:201–9. [PubMed: 19290712]
4. Waters EA, Weinstein ND, Colditz GA, Emmons KM. Reducing aversion to side effects in preventive medical treatment decisions. *Journal of Experimental Psychology: Applied* 2007;13:11–21. [PubMed: 17385998]
5. Port ER, Montgomery LL, Heerdt AS, Borgen PI. Patient reluctance toward tamoxifen use for breast cancer primary prevention. *Annals of Surgical Oncology* 2001;8:580–5. [PubMed: 11508619]
6. Wroe AL, Turner N, Salkovskis PM. Understanding and predicting parental decisions about early childhood immunizations. *Health Psychology* 2004;23:33. [PubMed: 14756601]
7. Amsterlaw J, Zikmund-Fisher BJ, Fagerlin A, Ubel PA. Can avoidance of complications lead to biased healthcare decisions? *Judgment and Decision Making* 2006;1:64.
8. Waters EA, Weinstein ND, Colditz GA, Emmons KM. Aversion to side effects in preventive medical treatment decisions. *British Journal of Health Psychology* 2007;12:383–401. [PubMed: 17640453]
9. Ferrer RA, Green PA, Barrett LF. Affective Science Perspectives on Cancer Control: Strategically Crafting a Mutually Beneficial Research Agenda. *Perspectives on Psychological Science* 2015;10:328–45. [PubMed: 25987511]
10. Ferrer RA, Klein WMP, Lerner JS, Reyna VF, Keltner D. Emotions and health decision making: Extending the Appraisal Tendency Framework to improve health and health care In: Roberto C, Kawachi I, eds. *Behavioral economics and public health*. New York, NY: Oxford University Press; 2015.

11. Suter RS, Pachur T, Hertwig R. How Affect Shapes Risky Choice: Distorted Probability Weighting Versus Probability Neglect. *Journal of Behavioral Decision Making* 2015:n/a–n/a.
12. Pachur T, Hertwig R, Wolkewitz R. The affect gap in risky choice: Affect-rich outcomes attenuate attention to probability information. *Decision* 2014;1:64.
13. Asgarova R, Macaskill AC, Robinson BJ, Hunt MJ. Probability Discounting and Cardiovascular Risk: The Effect of Side-Effect Severity and Framing. *The Psychological Record* 2017:1–11.
14. Suter RS, Pachur T, Hertwig R, Endestad T, Biele G. The neural basis of risky choice with affective outcomes. *PloS one* 2015;10:e0122475. [PubMed: 25830918]
15. Loewenstein GF, Weber EU, Hsee CK, Welch N. Risk as feelings. *Psychological Bulletin* 2001;127:267–86. [PubMed: 11316014]
16. Slovic P, Finucane ML, Peters E, MacGregor DG. Risk as Analysis and Risk as Feelings: Some Thoughts about Affect, Reason, Risk, and Rationality. *Risk Analysis* 2004;24:311–22. [PubMed: 15078302]
17. Han S, Lerner JS, Keltner D. Feelings and consumer decision making: The appraisal-tendency framework. *Journal of Consumer Psychology* 2007;17:158–68.
18. Lerner JS, Keltner D. Beyond valence: Toward a model of emotion-specific influences on judgement and choice. *Cognition & Emotion* 2000;14:473–93.
19. Lerner JS, Keltner D. Fear, anger, and risk. *Journal of personality and social psychology* 2001;81:146. [PubMed: 11474720]
20. Smith CA, Ellsworth PC. Patterns of cognitive appraisal in emotion. *Journal of personality and social psychology* 1985;48:813. [PubMed: 3886875]
21. Tiedens LZ, Linton S. Judgment under emotional certainty and uncertainty: the effects of specific emotions on information processing. *Journal of personality and social psychology* 2001;81:973. [PubMed: 11761319]
22. Witte K, Allen M. A Meta-Analysis of Fear Appeals: Implications for Effective Public Health Campaigns. *Health Education & Behavior* 2000;27:591–615. [PubMed: 11009129]
23. Ruiter RAC, Kessels LTE, Peters G-JY, Kok G. Sixty years of fear appeal research: Current state of the evidence. *International Journal of Psychology* 2014;49:63–70. [PubMed: 24811876]
24. Rivers SE, Reyna VF, Mills B. Risk taking under the influence: A fuzzy-trace theory of emotion in adolescence. *Developmental Review* 2008;28:107–44. [PubMed: 19255597]
25. Ferrer RA, Klein WMP. Risk perceptions and health behavior. *Current Opinion in Psychology* 2015;5:85–9. [PubMed: 26258160]
26. Ferrer RA, Klein WMP, Persoskie A, Avishai-Yitshak A, Sheeran P. The Tripartite Model of Risk Perception (TRIRISK): Distinguishing Deliberative, Affective, and Experiential Components of Perceived Risk. *ann behav med* 2016;50:653–63. [PubMed: 26961206]
27. Hay J, Shuk E, Cruz G, Ostroff J. Thinking Through Cancer Risk: Characterizing Smokers' Process of Risk Determination. *Qualitative Health Research* 2005;15:1074–85. [PubMed: 16221880]
28. Lipkus IM, Kuchibhatla M, McBride CM, et al. Relationships among breast cancer perceived absolute risk, comparative risk, and worries. *Cancer Epidemiology Biomarkers and Prevention* 2000;9:973–5.
29. McCaul KD, Branstetter AD, Schroeder DM, Glasgow RE. What is the relationship between breast cancer risk and mammography screening? A meta-analytic review. *Health Psychology* 1996;15:423–9. [PubMed: 8973921]
30. Ferrer RA, Klein WMP, Avishai A, Jones K, Villegas ME, Sheeran P. When does risk perception predict protection motivation? A person-by-situation analysis. *PLOS ONE* in press.
31. Weinstein ND, Kwitel A, McCaul KD, Magnan RE, Gerrard M, Gibbons FX. Risk perceptions: Assessment and relationship to influenza vaccination. *Health Psychology* 2007;26:146–51. [PubMed: 17385965]
32. Brewer NT, Weinstein ND, Cuite CL, Herrington JE, Jr. Risk perceptions and their relation to risk behavior. *ann behav med* 2004;27:125–30. [PubMed: 15026296]
33. Schwarzer R. Optimism, Vulnerability, and self-beliefs as health-related cognitions: A systematic overview. *Psychology & Health* 1994;9:161–80.

34. Lench HC, Flores SA, Bench SW. Discrete emotions predict changes in cognition, judgment, experience, behavior, and physiology: a meta-analysis of experimental emotion elicitation. *Psychological bulletin* 2011;137:834. [PubMed: 21766999]
35. Burton CM, King LA. The health benefits of writing about intensely positive experiences. *Journal of research in personality* 2004;38:150–63.
36. Kassam KS, Mendes WB. The effects of measuring emotion: Physiological reactions to emotional situations depend on whether someone is asking. *PloS one* 2013;8:e64959. [PubMed: 23785407]
37. Lieberman MD, Eisenberger NI, Crockett MJ, Tom SM, Pfeifer JH, Way BM. Putting feelings into words. *Psychological science* 2007;18:421–8. [PubMed: 17576282]
38. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. *Journal of the Royal Statistical Society Series B (Methodological)* 1995;57:289–300.
39. McDonald JH. Multiple tests. *Handbook of Biological Statistics*. 3rd ed Baltimore, Maryland: Sparky House Publishing; 2014:233–6.
40. Preacher KJ, Selig JP. Advantages of Monte Carlo confidence intervals for indirect effects. *Communication Methods and Measures* 2012;6:77–98.
41. Monte Carlo method for assessing mediation: An interactive tool for creating confidence intervals for indirect effects [Computer software]. 2008 at <http://quantpsy.org/>
42. Ferrer RA, Stanley JT, Graff K, et al. The Effect of Emotion on Visual Attention to Information and Decision Making in the Context of Informed Consent Process for Clinical Trials. *Journal of Behavioral Decision Making* 2016;29:245–53.
43. Rottenstreich Y, Hsee CK. Money, kisses, and electric shocks: On the affective psychology of risk. *Psychological science* 2001;12:185–90. [PubMed: 11437299]
44. Nabi RL. Exploring the framing effects of emotion: do discrete emotions differentially influence information accessibility, information seeking, and policy preference? *Communication Research* 2003;30:224–47.
45. Lerner JS, Gonzalez RM, Small DA, Fischhoff B. Effects of fear and anger on perceived risks of terrorism a national field experiment. *Psychological science* 2003;14:144–50. [PubMed: 12661676]
46. Hay JL, Buckley TR, Ostroff JS. The role of cancer worry in cancer screening: a theoretical and empirical review of the literature. *Psycho Oncology* 2005;14:517–34. [PubMed: 15490428]
47. Cameron LD. Illness risk representations and motivations to engage in protective behavior: The case of skin cancer risk. *Psychology & Health* 2008;23:91–112. [PubMed: 25159909]
48. Chapman GB, Coups EJ. Emotions and preventive health behavior: Worry, regret, and influenza vaccination. *Health Psychology* 2006;25:82–90. [PubMed: 16448301]
49. Ferrer RA, Bergman HE, Klein WMP. Worry as a Predictor of Nutrition Behaviors: Results From a Nationally Representative Survey. *Health Education & Behavior* 2013;40:88–96. [PubMed: 22505569]
50. Janssen E, Waters EA, van Osch L, Lechner L, de Vries H. The importance of affectively-laden beliefs about health risks: The case of tobacco use and sun protection. *J Behav Med* 2014;37:11–21. [PubMed: 23073599]
51. Peters E, Lipkus I, Diefenbach MA. The functions of affect in health communications and in the construction of health preferences. *Journal of Communication* 2006;56:S140–S62.
52. Waters EA, Pachur T, Colditz GA. Side Effect Perceptions and Their Impact on Treatment Decisions in Women. *Medical Decision Making* 2016.
53. Fraenkel L, Stolar M, Bates JR, et al. Variability in Affect and Willingness to Take Medication. *Medical Decision Making* 2017:0272989X17727002.
54. Shrout PE, Bolger N. Mediation in experimental and nonexperimental studies: New procedures and recommendations. *Psychological methods* 2002;7:422–45. [PubMed: 12530702]
55. Hayes AF. Beyond Baron and Kenny: Statistical mediation analysis in the new millennium. *Communication monographs* 2009;76:408–20.

56. Ferrer RA, Klein WM, Graff KA. Self-affirmation increases defensiveness toward health risk information among those experiencing negative emotions: Results from two national samples. *Health Psychology* 2017;36:380. [PubMed: 28206787]
57. Ferrer RA, Maclay A, Litvak PM, Lerner JS. Revisiting the Effects of Anger on Risk-Taking: Empirical and Meta-Analytic Evidence for Differences Between Males and Females. *Journal of Behavioral Decision Making* 2017;30:516–26.
58. Ferrer RA, Maclay A, Litvak PM, Lerner JS. Revisiting the Effects of Anger on Risk-Taking: Empirical and Meta-Analytic Evidence for Differences Between Males and Females. *Journal of Behavioral Decision Making* 2017;30:516–26.



**Risk of cancer and heart disease with
and without drug**




Figure 1.
Black-and-white version of array corresponding to the tradeoff scenario in which the pill reduced cancer risk, but raised heart disease risk.




Figure 2. Mediation model illustrating indirect effect of emotion condition on willingness via changes in the five risk perception scales that were influenced by the emotion condition.

Table 1.

Participant characteristics

	Study condition			F-test or χ^2
	Neutral	Anger	Fear	
Age	37.67 (12.06)	38.99 (13.05)	38.32 (12.08)	1.79
Sex (female)	355 (52.8)	333 (52.8)	332 (52.2)	0.054
Race				
White	511 (75.5)	486 (76.8)	493 (77.2)	0.63
Asian	74 (10.9)	78 (12.3)	65 (10.2)	1.51
Hispanic	50 (7.5)	51 (8.2)	55 (8.8)	0.69
Black	51 (7.5)	47 (7.4)	54 (8.5)	0.58
Other race	39 (5.8)	30 (4.7)	37 (5.8)	0.90
Education (7-pt scale)	5.09 (1.57)	5.08 (1.61)	5.04 (1.57)	0.19
Health status (5-pt scale)	3.34 (1.00)	3.34 (0.98)	3.28 (0.99)	0.78
Manipulation check				
Current anger (5-pt scale)	1.48 (0.90)	2.79 (1.26)	2.03 (1.21)	113.17***
Current fear (5-pt scale)	1.63 (0.96)	2.13 (1.14)	2.56 (1.26)	57.15***

* $p < .05$;

** $p < .01$;

*** $p < .001$

ANOVA and chi-square models tested whether participant characteristics and current emotions were significantly different across emotion conditions (anger, fear, neutral).

Effects of participant characteristics and study condition on willingness to use the medication in the benchmark and tradeoff scenarios.

Table 2.

	Benchmark scenario (n = 1,004)			Tradeoff scenario (n = 1,948)		
	β	p-value	ω^2	β	p-value	ω^2
Age	0.14***	<.001	0.020	0.0082	.72	-0.00046
Sex (male)						
Male	ref			ref		
Female	-0.12	0.054	0.0027	-0.16***	<.001	0.0060
Race						
White	-0.15*	.039	0.0032	-0.28***	<.001	0.013
Asian/Pacific Islander	0.23**	.010	0.0056	0.35***	<.001	0.012
Hispanic	-0.062	.59	-0.00071	0.37***	<.001	0.010
Black	-0.25*	.044	0.0030	0.021	.80	-0.00048
Other race	-0.18	.45	-0.00043	-0.15	.33	<0.0001
Education	0.0032	.92	-0.00099	-0.032	.16	0.00051
Health status	0.12***	<.001	0.014	0.086***	<.001	0.0068
Pill's target health condition						
Cancer	ref			ref		
Heart disease	-0.47***	<.001	0.019	-0.32***	<.001	0.0069
STIs	-0.70***	<.001	0.055	-0.17***	<.001	0.0024
Loss in sexual pleasure	-0.76***	<.001	0.065	-0.39***	<.001	0.016
Emotion condition, adjusted (unadjusted) values						
Neutral	ref			ref		
Anger	-0.041 (-0.035)	.61 (.65)	-0.00072 (-0.00079)	0.066 (0.079)	.22 (.15)	-0.00019 (0.00053)
Fear	-0.022 (-0.028)	.86 (.72)	-0.00089 (-0.00087)	0.14* (0.13**)	.009 (.012)	0.0030 (0.0025)

* $p < .05$;

** $p < .01$;

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

 $p < .001$

ref = reference category

The effects for the tradeoff scenario do not differ if analyzed using only the participants who also completed the baseline scenario. All continuous variables were standardized; statistics should be interpreted as standardized beta coefficients.

Adjusted models included age, sex, race/ethnicity, health status, and target health condition as covariates.

Table 3.

Effects of emotion condition on perceived risk (PR)

	Perceived risk of target condition				Perceived risk of side effect			
	If took pill		If did not take pill		If took pill		If did not take pill	
	β	ω^2	β	ω^2	β	ω^2	β	ω^2
<i>Deliberative risk perceptions</i>								
Emotion condition								
Anger	0.072	0.13	0.028	0.58	0.10	0.038	0.0019	0.32
Fear	0.0087	0.86	-0.035	0.49	0.034	0.47	-0.00028	0.022
<i>Experiential risk perceptions</i>								
Emotion condition								
Anger	0.041	0.55	0.099	0.16	0.028	0.7	-0.00048	0.62
Fear	-0.00036	0.99	-0.0068	0.92	0.075	0.31	2.1E-05	0.03
<i>Affective risk perceptions</i>								
Emotion condition								
Anger	0.87	0.15	0.00058	0.36	0.17 ^a	0.002	0.0046	0.41
Fear	0.034	0.55	-0.00035	0.12	0.015	0.83	-0.00051	0.28

ref = reference category

Adjusted models included age, sex, race/ethnicity, health status, and target health condition as covariates.

* $p < .05$;

** $p < .01$;

*** $p < .001$

^a Statistically significant effect in models adjusted for multiple comparisons when $Q = .05$ (all effects remained significant when $Q = .25$).

Table 4

Mediational pathways – Indirect effect of emotion condition on willingness to use medication through effects on perceived risk (PR).

Risk perception tested	Emotion on PR		PR on willingness		Emotion on willingness		Indirect effect (a*b)	
	Anger (a _e)	Fear (a _f)	PR on willingness (b)	Anger (c' a)	Fear (c' f)	Emotion on willingness	Anger Fear	
Conditional on taking pill								
1) Affective PR of side effect	0.17**	0.015	-0.28***	0.13	0.25**	-0.047**	-0.0041	
2) Deliberative PR of side effect	0.096*	0.028	-0.061	0.089	0.28**	-0.0059	-0.0017	
Conditional on <i>not</i> taking pill								
3) Deliberative PR of side effect	0.048	0.11*	0.53***	0.065	0.21*	0.026	0.059*	
4) Experiential PR of side effect	0.032	0.13*	0.37***	0.069	0.19*	0.012	0.050*	
5) Affective PR of target condition	0.052	0.12*	0.37***	0.062	0.20*	0.019	0.045*	

* $p < .05$;

** $p < .01$;

*** $p < .001$

Parentetical abbreviations correspond to labels in Figure 2.

All models adjust for age, sex, race/ethnicity, health status, and target health condition.